HB0064 is a hemp regulation reform bill that updates Illinois law to align more closely with federal hemp standards and to clarify how hemp and hemp-derived cannabinoids are treated in consumer products. It amends the Illinois Food, Drug and Cosmetic Act to state that a food, food ingredient, dietary supplement, cosmetic, or other consumer product is not adulterated solely because it contains hemp or hemp-derived cannabinoids such as Delta-9 THC, Delta-8 THC, or THCa, so long as the hemp meets the federal definition of hemp. It also revises the Industrial Hemp Act to conform state definitions, licensing, and rulemaking provisions to the federal Domestic Hemp Production Program.
The bill adds more detailed state oversight for hemp products intended for human consumption and retail sale in Illinois. It requires such products to meet federal requirements and rules adopted by the Department of Public Health, to be packaged with specified information, and to comply with contamination limits. It also directs the Department of Agriculture to adopt rules for distribution and retail sale of hemp products and provides that hemp products intended for inhalation or ingestion with detectable cannabinoids may not be sold to persons under 21. Products sold in violation of these provisions would be treated as adulterated or misbranded under the Food, Drug and Cosmetic Act and other applicable state laws.
The bill’s impact on state law would be to create a clearer legal framework for hemp-derived consumer products while preserving state enforcement authority over safety, labeling, and age restrictions. It would modify multiple sections of the Industrial Hemp Act, update licensing and inspection rules for hemp cultivation and processing, and require agency rulemaking to implement the new standards. It also narrows the circumstances under which hemp-containing products can be treated as adulterated, which could affect manufacturers, retailers, cultivators, processors, and regulators.
The available legislative context suggests the bill was introduced as a regulatory modernization measure rather than a controversial policy shift, but it was not advanced in the available record and was re-referred to the Rules Committee. Because there are no committee transcripts or recorded votes provided, there is no direct evidence of floor debate or formal opposition in the materials supplied. The overall tone implied by the bill text is technical and administrative, focused on harmonizing Illinois law with federal hemp rules and establishing consumer safety standards.
The main points of potential contention are likely to center on hemp-derived intoxicating products, especially Delta-8 THC and similar cannabinoids, age limits, packaging requirements, and the balance between market access and public health regulation. Stakeholders who may favor the bill include hemp growers, processors, and retailers seeking legal certainty, while those more concerned with youth access, product safety, or intoxicating hemp products may support stricter enforcement or oppose broader product legality.
HB0064 would amend the Illinois Food, Drug and Cosmetic Act and the Industrial Hemp Act to align state hemp definitions and regulatory requirements with federal law, while adding state-specific rules for hemp-derived consumer products. It would direct the Department of Agriculture and Department of Public Health to adopt implementing rules, establish packaging and safety requirements, and prohibit sale of certain hemp cannabinoid products to persons under 21. It would also make hemp products sold in violation of the new requirements subject to adulteration or misbranding enforcement under state law.
The bill appears to be framed as a technical regulatory update with a generally pro-industry, pro-clarity orientation, rather than a highly partisan measure. The available record shows no committee testimony or votes, so there is no documented public debate in the materials provided. The last recorded action—re-referral to the Rules Committee—suggests the bill did not move forward in the available legislative history.
Likely areas of contention include whether hemp-derived cannabinoids such as Delta-8 THC and THCa should be treated like ordinary hemp products, how strictly to regulate products intended for ingestion or inhalation, and whether the under-21 sales restriction is sufficient. Supporters would likely emphasize legal certainty for hemp businesses and conformity with federal law, while critics may focus on youth access, labeling, contamination standards, and the possibility that the bill could broaden availability of intoxicating hemp products.